JOURNAL OF THE CZECH PHARMACEUTICAL SOCIETY AND THE SLOVAK PHARMACEUTICAL SOCIETY

Čes. slov. farm. 2023, 72(6):287-295 | DOI: 10.5817/CSF2023-6-287

Prospects of сomplex pharmaceutical composition application for pharmacological correction of metabolic syndrome

Kateryna Kalko1,*, Nadia Dukhnich2, Oksana Mishchenko2, Viktor Khomenko3, Olena Toziuk4
1 Department of Pharmacology and Drug Technology of I. I. Mechnikov Odesa National University, Odesa, Ukraine
2 Department of Clinical Pharmacology of the National University of Pharmac, Kharkiv, Ukraine
3 Department of Pharmacology and Pharmacy of the Donetsk National Medical University, Lyman, Ukraine
4 Department of Pharmacy, National Pirogov Memorial Medical University, Vinnytsya, Ukraine

Metabolic syndrome (MetS) is a symptomatic complex characterized by insulin resistance, impaired prooxidant-antioxidantbalance of the body with the development of subchronic inflammation, and dyslipidemia. The aim of the study is to investigate the effect of a complex pharmaceutical composition (CPC) (antioxidants and metabolitotropic agents), which is widely used in medical practice in Ukraine as a multivitamin complex, on experimental metabolic syndrome in rats. The effectof CPC on the correction of experimental MetS in rats, induced by a high content of carbohydrates and fats in the diet, was assessed. MetS in rats was characterized by a decrease in the sensitivity of cells to insulin, increased glucose content, and aviolation of its utilization, prooxidant-antioxidant disbalance. The results of the conducted studies indicate the positive effect of CPC, which contains ethyl esters of omega-3 acids, vitamin E, coenzyme Q10, zinc, vitamin A, biotin, and selenium, on the sensitivity of cells to insulin, glucose utilization, duration of hyperglycemia and indicators of free radical oxidation processes and antioxidant defense systems in rats with experimental MetS. These results prove the feasibility of using CPC to correct metabolic syndrome.

Keywords: metabolic syndrome; hyperglycemia; sensitivity of cells to insulin; prooxidant-antioxidant balance

Received: June 4, 2023; Accepted: November 7, 2023; Published: June 1, 2023  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Kalko K, Dukhnich N, Mishchenko O, Khomenko V, Toziuk O. Prospects of сomplex pharmaceutical composition application for pharmacological correction of metabolic syndrome. Čes. slov. farm. 2023;72(6):287-295. doi: 10.5817/CSF2023-6-287.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Bovolini A, Garcia J, Andrade MA, Duarte JA. Metabolic Syndrome Pathophysiology and Predisposing Factors. Int. J. Sports Med. 2021; 42(3), 199-214. doi: 10.1055/a-1263-0898 Go to original source... Go to PubMed...
    2. Kalko K. O. "Korvitin®" - new therapeutic opportunities Pharmacologyonline 2021; 2, 1310-1316. Avaiable from:https://pharmacologyonline.silae.it/files/archives/2021/ vol2/PhOL_2021_2_A144_Kalko.pdf
    3. Gurka MJ, Guo Y, Filipp SL, DeBoer MD. Metabolic syndrome severity is significantly associated with future coronary heart disease in Type 2 diabetes. Cardiovasc. Diabetol. 2018; 17, 17. doi: 10.1186/s12933-017-0647-y Go to original source... Go to PubMed...
    4. Lopez-Candales A, Hernández Burgos PM, Hernandez-Suarez DF, Harris D. Linking chronic inflammation with cardiovascular disease: From normal aging to the metabolic syndrome. J. Nat. Sci. 2017; 3, e341
    5. Castillo-Díaz LA, Ruiz-Pacheco JA, Elsawy MA, ReyesMartínez JE, Enríquez-Rodríguez AI. Self-Assembling Peptides as anEmerging Platform for the Treatment of Metabolic Syndrome. Int. J. Nanomedicine 2020; 15, 10349-10370. doi: 10.2147/IJN.S278189 Go to original source... Go to PubMed...
    6. Carrier A. Metabolic Syndrome and Oxidative Stress: A Complex Relationship. Antioxid. Redox Signal 2017; 26(9), 429-431. doi: 10.1089/ars.2016.6929 Go to original source... Go to PubMed...
    7. McCracken E, Monaghan M, Sreenivasan S. Pathophysiology of the metabolic syndrome. Clin. Dermatol 2018; 36(1), 14-20. doi: 10.1016/j.clindermatol.2017.09.004 Go to original source... Go to PubMed...
    8. Gregório BM, De Souza DB, de Morais Nascimento FA, Pereira LM, Fernandes-Santos C. The potential role of antioxidants in metabolic syndrome. Curr. Pharm. Des. 2016; 22(7), 859-869. doi: 10.2174/1381612822666151209152352 Go to original source... Go to PubMed...
    9. Alam MA, Subhan N, Rahman MM, Uddin SJ, Reza HM, Sarker SD. Effect of citrus flavonoids, naringin and naringenin, on metabolic syndrome and their mechanisms of action. Adv. Nutr. 2014; 5(4), 404-417. doi: 10.3945/an.113.005603. Go to original source... Go to PubMed...
    10. Dludla PV, Nyambuya TM, Orlando P, Silvestri S, Mxinwa V, Mokgalaboni K, Nkambule BB, Louw J, Muller CJF, Tiano L. Theimpact of coenzyme Q10 on metabolic and cardiovascular disease profiles in diabetic patients: A systematic review and meta-analysis of randomized controlled trials. Endocrinol. Diabetes Metab. 2020; 3(2), e00118. doi: 10.1002/edm2.118 Go to original source... Go to PubMed...
    11. Dakshinamurti K. Vitamins and their derivatives in the prevention and treatment of metabolic syndrome diseases (diabetes). Can J. Physiol. Pharmacol. 2015; 93(5), 355-362. doi: 10.1139/cjpp-2014-0479 Go to original source... Go to PubMed...
    12. Beydoun MA, Chen X, Jha K, Beydoun HA, Zonderman AB, Canas JA. Carotenoids, vitamin A, and their association with the metabolic syndrome: a systematic review and meta-analysis. Nutr. Rev. 2019; 77(1), 32-45. doi: 10.1093/nutrit/nuy044 Go to original source... Go to PubMed...
    13. Farajbakhsh A, Mazloomi SM, Mazidi M, Rezaie P, Akbarzadeh M, Ahmad SP, Ferns GA, Ofori-Asenso R, Babajafari S. Sesame oil and vitamin E co-administration may improve cardiometabolic risk factors in patients with metabolic syndrome: a randomized clinical trial. Eur. J. Clin. Nutr. 2019; 73(10), 1403-1411. doi: 10.1038/s41430-019-0438-5 Go to original source... Go to PubMed...
    14. Directive 2010/63/EU of the European Parliament and of the Council of September 22 2010 on the protection of animals used for scientific purposes. Official Journal of the European Union 2010; 33-79.
    15. AEVIT PREMIUM: instructions for medical use [Electronic resource] - Access mode: https://compendium.com.ua/info/350158/aevit-premium/
    16. Siofor: instructions for medical treatment [Electronic resource] - Access mode: https://mozdocs.kiev.ua/likiview.php?id=38861
    17. Vitamin E instructions for medical treatment [Electronic resource] - Access mode: https://www.lekhim.ua/ru/alfa-tokoferola-acetat-vitamin-e_dose-100-mgml-po-20ml-no-1
    18. Kalko K. O., Drogovoz S. M., Mishchenko O. Ya., Komisarenko M. A., Komissarenko A. M., Bondariev Y. V., Moeen Dababneh. Administration of "CORVITIN®" as an off-label agent for pharmacological correction of metabolic syndrome. Problems of endocrine pathology 2021; 1, 97-102. https://www.jpep.endocrinology.org.ua/index.php/1/article/view/124 Go to original source...
    19. Rybolovlev Yu. R., Sidlyarov D. P., Afonin N. I. Predictive assessment of the safety of substances for humans by the constants oftheir biological activity. Toxicological aspects of the safety of finished dosage forms: astract report scientific conf. Moscow, December 16-18, 1981. M., 1981. P. 9-10.
    20. Geddawy A, Hussian M, Kamel MY, Kamal R, Ibrahim MA. Effects of Liraglutide and Vitamin E in Fructose-Induced MetabolicSyndrome in Rats. Pharmacology 2017; 9 (1-2), 48-56. doi: 10.1159/000449429. Go to original source... Go to PubMed...
    21. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulinresistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28, 412-419. Go to original source... Go to PubMed...
    22. Stefanov O. V. Preclinical studies of drugs (methodological recommendations). For order. Corresponding Member NAMS of Ukraine Kyiv: VD Avicenna, 2001.
    23. Truhacheva N. V. Mathematical statistics in medical-biological researches using the package statistics. Moscow, Russian Federation: GEOTAR-Media 2012.
    24. Russo B, Picconi F, Malandrucco I, Frontoni S. Flavonoids and Insulin-Resistance: From Molecular Evidences to Clinical Trials. Int. J. Mol. Sci. 2019; 20(9), 2061. doi: 10.3390/ijms20092061 Go to original source... Go to PubMed...
    25. Dakshinamurti K. Vitamins and their derivatives in the prevention and treatment of metabolic syndrome diseases (diabetes). Can. J. Physiol. Pharmacol. 2015; 93(5), 355-362. doi: 10.1139/cjpp-2014-0479 Go to original source... Go to PubMed...
    26. Albracht-Schulte K, Kalupahana NS, Ramalingam L, Wang S, Rahman SM, Robert-McComb J, Moustaid-Moussa N. Omega-3 fatty acids in obesity and metabolic syndrome: a mechanistic update. J. Nutr. Biochem. 2018; 58, 1-16. doi:10.1016/j.jnutbio.2018.02.012 Go to original source... Go to PubMed...
    27. Tortosa-Caparrós E, Navas-Carrillo D, Marín F, Orenes-Piñero E. Anti-inflammatory effects of omega 3 and omega 6 polyunsaturated fatty acids in cardiovascular disease and metabolic syndrome. Crit. Rev. Food. Sci. Nutr. 2017; 57(16), 3421-3429. doi: 10.1080/10408398.2015.1126549 Go to original source... Go to PubMed...
    28. Kawada T. Omega-3 polyunsaturated fatty acids and metabolic syndrome. Clin. Nutr. 2020; 39(7), 2319. doi:10.1016/j.clnu.2020.05.033 Go to original source... Go to PubMed...
    29. Geddawy A, Hussian M, Kamel MY, Kamal R, Ibrahim MA. Effects of Liraglutide and Vitamin E in Fruc tose-Induced MetabolicSyndrome in Rats. Pharmacology. 2017; 99(1-2), 48-56. doi: 10.1159/000449429 Go to original source... Go to PubMed...
    30. Zozina VI, Covantev S, Goroshko OA, Krasnykh LM, Kukes VG. Coenzyme Q10 in Cardiovascular and Metabolic Diseases:Current State of the Problem. Curr. Cardiol. Rev. 2018; 14(3), 164-174. doi: 10.2174/1573403X14666180416115428 Go to original source... Go to PubMed...
    31. Dludla PV, Orlando P, Silvestri S, Marcheggiani F, Cirilli I, Nyambuya TM, Mxinwa V, Mokgalaboni K, Nkambule BB, Johnson R, Mazibuko-Mbeje SE, Muller CJF, Louw J, Tiano L. Coenzyme Q10 Supplementation Improves Adipokine Levels and Alleviates Inflammation and Lipid Peroxidation in Conditions of Metabolic Syndrome: A Meta-Analysis of RandomizedControlled Trials. Int. J. Mol. Sci. 2020; 21(9), 3247. doi: 10.3390/ijms21093247. Go to original source... Go to PubMed...
    32. Aguilera-Mendez A, Hernández-Equihua MG, Rueda-Rocha AC, Guajardo-López C, Nieto-Aguilar R, Serrato-Ochoa D, Ruíz Herrera LF, Guzmán-Nateras JA. Protective effect of supplementation with biotin against high-fructose-induced metabolic syndromein rats. Nutr. Res. 2018; 57, 86-96. doi: 10.1016/j.nutres.2018.06.007 Go to original source... Go to PubMed...
    33. Miao X, Sun W, Fu Y, Miao L, Cai L. Zinc homeostasis in the metabolic syndrome and diabetes. Front. Med. 2013; 7(1), 31-52. doi: 10.1007/s11684-013-0251-9 Go to original source... Go to PubMed...
    34. Aguilera-Mendez A, Hernández-Equihua MG, Rueda-Rocha AC, Guajardo-López C, Nieto-Aguilar R, Serrato-Ochoa D, Ruíz Herrera LF, Guzmán-Nateras JA. Protective effect of supplementation with biotin against high-fructose-induced metabolic syndrome in rats. Nutr. Res. 2018; 57, 86-96. doi: 10.1016/j.nutres.2018.06.007 Go to original source... Go to PubMed...
    35. Retondario A, Fernandes R, Rockenbach G, Alves MA, Bricarello LP, Trindade EBSM, Vasconcelos FAG. Selenium intake and metabolic syndrome: A systematic review. Clin. Nutr. 2019; 38(2), 603-614. doi: 10.1016/j.clnu.2018.02.021 Go to original source... Go to PubMed...
    36. Beydoun MA, Chen X, Jha K, Beydoun HA, Zonderman AB, Canas JA. Carotenoids, vitamin A, and their association with the metabolic syndrome: a systematic review and meta-analysis. Nutr. Rev. 2019; 7(1), 32-45. doi: 10.1093/nutrit/nuy044. Go to original source... Go to PubMed...

    Return to the content


    Czech and Slovak Pharmacy

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.